Mycoplasma pneumoniae and Chlamydia pneumoniae in pediatric community-acquired pneumonia: comparative efficacy and safety of clarithromycin vs. erythromycin ethylsuccinate.
about
Diagnosis of Mycoplasma pneumoniae pneumonia in children.British Thoracic Society Guidelines for the Management of Community Acquired Pneumonia in Childhood.In vitro activity of CEM-101, a new fluoroketolide antibiotic, against Chlamydia trachomatis and Chlamydia (Chlamydophila) pneumoniae.Molecular diagnosis of Chlamydia pneumoniae infection.Chlamydia pneumoniae and atherosclerosis: critical assessment of diagnostic methods and relevance to treatment studiesChlamydia pneumoniae serology: importance of methodology in patients with coronary heart disease and healthy individualsVariation in colonization, ADP-ribosylating and vacuolating cytotoxin, and pulmonary disease severity among mycoplasma pneumoniae strains.In vitro activities of ABT-773 and other antimicrobials against human mycoplasmas.In vitro activities of azithromycin, clarithromycin, erythromycin, and tetracycline against 13 strains of Chlamydia pneumoniaeIn vitro activities of azithromycin and doxycycline against 15 isolates of Chlamydia pneumoniaeIn vitro activity of trovafloxacin against Chlamydia pneumoniaePersistence of community-acquired respiratory distress syndrome toxin-producing Mycoplasma pneumoniae in refractory asthma.Enrofloxacin and macrolides alone or in combination with rifampicin as antimicrobial treatment in a bovine model of acute Chlamydia psittaci infection.Respiratory tract infection with Mycoplasma pneumoniae in interleukin-12 knockout mice results in improved bacterial clearance and reduced pulmonary inflammationMycoplasma pneumoniae and its role as a human pathogen.Role of Atypical Pathogens and the Antibiotic Prescription Pattern in Acute Bronchitis: A Multicenter Study in Korea.Intranasal interleukin-12 therapy inhibits Mycoplasma pneumoniae clearance and sustains airway obstruction in murine pneumoniaSerological cross-reactions between Bartonella and Chlamydia species: implications for diagnosisMycoplasma pneumoniae in children with acute and refractory asthma.Infectious causes of chronic inflammatory diseases and cancerTigecycline therapy significantly reduces the concentrations of inflammatory pulmonary cytokines and chemokines in a murine model of Mycoplasma pneumoniae pneumonia.Evaluation of four commercial IgG- and IgM-specific enzyme immunoassays for detecting Mycoplasma pneumoniae antibody: comparison with particle agglutination assay.Optimal sampling sites and methods for detection of pathogens possibly causing community-acquired lower respiratory tract infections.In vitro activity of AZD0914, a novel DNA gyrase inhibitor, against Chlamydia trachomatis and Chlamydia pneumoniae.Genetic and culture-based approaches for detecting macrolide resistance in Chlamydia pneumoniae.Effect of prolonged treatment with azithromycin, clarithromycin, or levofloxacin on Chlamydia pneumoniae in a continuous-infection Model.In vitro activity of ABT 773, a new ketolide antibiotic, against Chlamydia pneumoniae.In vitro activities of gemifloxacin (SB 265805, LB20304) against recent clinical isolates of Chlamydia pneumoniae.In vitro susceptibilities of Chlamydia pneumoniae isolates from German patients and synergistic activity of antibiotic combinationsRapid detection of Chlamydia pneumoniae by PCR-enzyme immunoassay.In vitro activity of a new 8-methoxyquinolone, BAY 12-8039, against Chlamydia pneumoniae.Microbiologic efficacy of azithromycin and susceptibilities to azithromycin of isolates of Chlamydia pneumoniae from adults and children with community-acquired pneumonia.Evaluation of Chlamydia immunoglobulin M (IgM), IgG, and IgA rELISAs Medac for diagnosis of Chlamydia pneumoniae infectionImmunopathogenesis of Chlamydia pneumoniae Infections in children.Clarithromycin Plus Intravenous Immunoglobulin Therapy Can Reduce the Relapse Rate of Kawasaki Disease: A Phase 2, Open-Label, Randomized Control StudySearching for the Holy Grail of acute otitis media.Microbiological efficacy of levofloxacin for treatment of community-acquired pneumonia due to Chlamydia pneumoniae.Mixed Chlamydia trachomatis Peptide Antigens Provide a Specific and Sensitive Single-Well Colorimetric Enzyme-Linked Immunosorbent Assay for Detection of Human AntiC. trachomatis Antibodies
P2860
Q24518991-9456249C-0E57-402E-B43D-2B4B88E48D77Q30478714-9BC07BAF-E116-4870-BA79-8D27DAFBBB4BQ33676151-613EF022-6856-47BD-AFC8-E76AD734CFAAQ33775972-67AC1EEE-AE9C-4D2C-A314-DFA4B1418ED6Q33905858-0742553E-1CD5-4EE6-9164-FF140AF217F9Q33972282-820C27E9-114A-4D06-9DA8-E918C4A6A158Q34172141-948241D1-144C-405A-B212-14EA699BED44Q34722730-82D09BAE-A762-40A0-B3C2-BE7D5870839DQ35121993-EE6B799E-727B-4522-BFAC-3CCBDEF93486Q35126064-D6D115B6-42C3-4831-93E8-944B92948994Q35138264-0498AA87-D70D-473A-B4F3-A68BF52A3C93Q35143057-C2DC2034-EB04-417B-B769-1DC6F50BB0BBQ35175244-164645CF-53DD-432F-A492-ABF5FB207FF7Q35689129-724B2F54-CAAE-46D9-90F1-F1CC5619A364Q35920629-93F7FCF4-B349-4535-9CAA-2DA7A31AD629Q36075452-C72E4882-087A-4A77-8159-359A9E892D00Q36421600-2B7FBF27-3C17-49BE-A0D6-413C2CFEECC3Q36546292-B7CDA4BB-E87F-4510-B456-B67A6CECC067Q36990325-CD6E76A8-83EB-476F-8257-0E3CDA8271BEQ37092667-B530D2C6-4A9A-46F3-9D47-4D6AF8477472Q37144834-0D4410FB-543A-4706-9012-3C9C0E146673Q37221174-7598ADB7-75CA-42D9-8FBD-9C09178F3C4CQ37329763-4B6ADDDC-642C-4953-9109-9D5C4D21E9E0Q37843405-6FC1FFD0-3F81-4E9B-994D-4BB5FD6DDC87Q37866577-EBDA8F85-369B-45A0-A44C-CCD311FC0429Q37872800-6F9B8B7D-FDD7-457E-A958-0E76572D5AE3Q37876885-F70AFCB0-2787-4A90-97A2-D1C93465E051Q37877492-6D59CF40-EE8D-40BD-A5BE-CC12C6A56E6FQ37878178-B57BF09D-46AA-42E7-AE6D-483CD0C3C166Q37880695-4FF19BE6-2C6F-45B4-977B-6ABAD0DE697AQ37881176-90071851-4567-43AA-8572-C58E4F9785EBQ37881682-2D8830E0-D0DB-437A-8D19-186DF261A8B7Q37883374-0624976E-CE94-4FBD-9E16-FDB09197184DQ37885660-A3199736-9F5E-472C-A733-ED0CB60E008DQ38374445-36B0C282-FBE0-4389-B972-9E3F3EE421ACQ40275705-3356FEFC-0AC2-44FA-A4CF-3623E84AA5C6Q42729698-74D1EF76-5849-417F-B0F5-CB7A422ECA20Q58599393-A6FF8C0A-3365-49AC-8A0A-6B0BB76F107C
P2860
Mycoplasma pneumoniae and Chlamydia pneumoniae in pediatric community-acquired pneumonia: comparative efficacy and safety of clarithromycin vs. erythromycin ethylsuccinate.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 1995
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Mycoplasma pneumoniae and Chla ...... . erythromycin ethylsuccinate.
@en
Mycoplasma pneumoniae and Chla ...... . erythromycin ethylsuccinate.
@nl
type
label
Mycoplasma pneumoniae and Chla ...... . erythromycin ethylsuccinate.
@en
Mycoplasma pneumoniae and Chla ...... . erythromycin ethylsuccinate.
@nl
prefLabel
Mycoplasma pneumoniae and Chla ...... . erythromycin ethylsuccinate.
@en
Mycoplasma pneumoniae and Chla ...... . erythromycin ethylsuccinate.
@nl
P2093
P1476
Mycoplasma pneumoniae and Chla ...... s. erythromycin ethylsuccinate
@en
P2093
G H Cassell
M R Hammerschlag
P304
P356
10.1097/00006454-199506000-00002
P577
1995-06-01T00:00:00Z